Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yupingfeng granule for stable COPD
ChiCTR2200060476Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- May 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Yupingfeng granules with Placebo (Yupingfeng granule simulating agent) (2 arms). Primary endpoint: Change in COPD Assessment Test (CAT) score. Planned start May 2022; status: not yet recruiting.
02
Drugs
yupingfeng
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2200060476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060476.